Cell-of-Origin, not Oncogenic Effect, Determines Desmoplastic Immune Exclusion in KRAS-Driven Liver Cancer
Preprint
Abstract
Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the two most common primary liver cancers and share common risk factors. Yet they exhibit distinct oncogenic driver landscapes and fundamentally different tumor microenvironments (TME), with iCCA characterised by dense desmoplastic stroma that limits therapeutic efficacy. Whether these differences reflect oncogenic context or the developmental lineage of the cancer cell has remained unresolved. Here, using syngeneic orthotopic murine models derived from CRISPR-engineered cholangiocyte and hepatocyte organoids each carrying Trp53 deletion and Kras G12D mutation, we show that cell-of-origin, not oncogenic pathway activation, is the dominant determinant of TME architecture. Spatial proteomics of ∼390,000 cells reveals that cholangiocyte-derived tumors develop a stromal barrier of peripherally enriched αSMA + cancer-associated fibroblasts (CAFs) that physically excludes immune cells and elevates PD-1/PD-L1 engagement, whereas hepatocyte derived tumors permit broader immune infiltration. Transcriptional variance partitioning confirms lineage as the primary source of gene expression divergence. Integrating murine and human transcriptomic and secretomic datasets, we identify LAMC2 and uPA as cholangiocyte lineage-specific secreted factors that trigger CAF activation. Genetic deletion of either factor markedly impairs iCCA formation in vivo . These findings establish that lineage-encoded secretory programmes create a desmoplastic and immune-excluded stroma and identify LAMC2 and uPA as functionally relevant modulators of TME in KRAS-driven iCCA.Keywords
Funding Information
- German Cancer Aid (70113858)
- Uniscientia Foundation
- European Research Council (101116823)
- Ministry of Science and Innovation, Spain (PID2024-160007OB-I00)
- Ministry of Science and Innovation, Spain (RYC2022-036321-I)
- European Commission (101077312)
This publication has 89 references indexed in Scilit:
- Single-cell transcriptomic profiling and machine learning identify S-nitrosylation-associated LAMC2 as a key prognostic driver in pancreatic cancerDiscover Oncology, 2025
- KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor RegressionAdvanced Science, 2025
- The multidimensional role of laminin γ2 (LAMC2) on cancer progressionCancer Genetics, 2025
- Cancer-Associated Fibroblasts in Intrahepatic CholangiocarcinomaThe American Journal of Pathology, 2024
- Oncogenic Roles of Laminin Subunit Gamma‐2 in Intrahepatic Cholangiocarcinoma via Promoting EGFR TranslationAdvanced Science, 2024
- Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World DataTargeted Oncology, 2024
- PLAU contributes to the development of cholangiocarcinoma via activating NF‐κB signaling pathwayCell Biology International, 2023
- Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United StatesHepatology, 2021
- Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research2018
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015